Inclusion Criteria:

          -  Patient must be ≥18 years of age

          -  Diagnosis of one of the following:

               -  MUM: Uveal melanoma with histological or cytological confirmed metastatic
                  disease. Or

               -  Non-MUM: Advanced cutaneous melanoma, colorectal cancer, or other solid tumor
                  that has progressed following prior standard therapies or that has no
                  satisfactory alternative therapies and has evidence of GNAQ/11 hotspot mutation

          -  Measurable disease

          -  Eastern Cooperative Oncology Group ≤1 and expected life expectancy of > 3 months

          -  Adequate organ function at screening

          -  Adequate contraceptive measures for non-sterilized male and female patients of
             childbearing potential

        Binimetinib Combination Additional Inclusion Criteria:

        • Adequate cardiac function represented by left ventricular ejection fraction (LVEF) ≥ 50%

        Crizotinib Combination Additional Inclusion Criteria:

          -  Prior chemotherapy other therapies as applicable or major surgeries must have been
             completed at least 4 weeks prior to initiation of crizotinib

          -  Patients with preexisting peripheral neuropathy can be included if it is Grade 1 or
             lower, prior to initiation of crizotinib

        Exclusion Criteria:

          -  Another malignancy

          -  Previous treatment with a PKC inhibitor

          -  Known MSI-H/dMMR tumors who have not previously received immune checkpoint inhibitors

          -  Adverse events from prior anti-cancer therapy that have not resolved

          -  Untreated or symptomatic central nervous system metastases

          -  Human immunodeficiency virus, acquired immunodeficiency syndrome related illness,
             hepatitis B virus, or hepatitis C virus

          -  Recent surgery or radiotherapy

          -  Females who are pregnant or breastfeeding

          -  Impaired cardiac function

          -  For patients receiving IDE196 powder-in-capsule (PIC) formulation or crizotinib,
             allergy to mammalian meat products and gelatin

        Binimetinib Combination Additional Exclusion Criteria

          -  Patient has received prior treatment with a MEK inhibitor

          -  History of interstitial lung disease

          -  History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to first dose

          -  History or current evidence of central serous retinopathy (CSR) or retinal vein
             occlusion (RVO); History of retinal degenerative disease

          -  Concurrent neuromuscular disorders that are associated with elevated creatine
             phosphokinase (CPK)

          -  Uncontrolled arterial hypertension despite medical treatment

          -  Allergy to binimetinib or its components

        Crizotinib Combination Additional Exclusion Criteria:

          -  Prior therapy directly targeting ALK, MET, or ROS1

          -  Spinal cord compression

          -  Carcinomatous meningitis or leptomeningeal disease

          -  History of pneumonitis or interstitial lung disease